ELDN net incomeQ2 2026-$31.63M
ELDN net income was -$31.63M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$11.22M a year earlier. For the full fiscal 2025 it was -$45.62M, compared with -$36.18M in fiscal 2024.
Eledon Pharmaceuticals Inc. (ELDN) financials
For the twelve months ended Jun 30, 2026, Eledon Pharmaceuticals Inc. reported -$98.56M of net income.
- Net income, TTM
- -$98.56M
- EPS, diluted, TTM
- -$0.91
- Cash
- $6.80M
- Total debt
- $0
- Market cap
- $232.8M
FY2016FY2025
ELDN revenue and earnings growth
ELDN EPSQ2 2026-$0.27
ELDN diluted EPS was -$0.27 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.52.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $0 |
| Research and development | $66.27M | $51.96M | $30.31M | $27.08M | $23.73M | $6.13M | $8.13M | $6.82M | $2.02M | $3.19M |
| Selling, general and admin | $16.98M | $18.61M | $12.69M | $12.70M | $13.13M | $10.05M | $6.06M | $7.24M | $11.10M | $1.94M |
| Operating income | - | - | -$43.00M | -$88.43M | -$36.87M | -$18.46M | -$16.05M | -$14.06M | -$13.12M | -$5.13M |
| Pre-tax income | -$45.58M | -$35.75M | -$116.54M | -$87.97M | -$36.86M | -$23.21M | -$16.01M | -$14.06M | -$13.12M | -$5.66M |
| Income tax | $35.0K | $431.0K | $0 | $0 | -$2.35M | -$404.0K | - | - | - | $0 |
| Net income | -$45.62M | -$36.18M | -$116.54M | -$87.97M | -$34.51M | -$22.81M | -$16.01M | -$14.06M | -$13.12M | -$5.66M |
| EPS, basic | -$0.52 | -$0.66 | -$4.73 | -$6.16 | -$2.33 | -$15.72 | -$24.42 | -$28.08 | -$41.40 | -$44.28 |
| EPS, diluted | -$0.52 | -$0.66 | -$4.73 | -$6.16 | -$2.33 | -$15.72 | -$24.42 | -$28.08 | -$41.40 | -$44.28 |
| Diluted shares | 81.8M | 48.5M | 24.6M | 14.3M | 14.8M | 1.5M | 655,526 | 500,297.333 | 259,867.222 | 21,263.722 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $22.81M | $20.55M | $4.61M | $56.41M | $84.83M | $114.19M | $8.79M | $12.97M | $17.30M | $1.12M |
| Short-term investments | $110.53M | $119.63M | $46.49M | $0 | - | - | - | - | - | - |
| Current assets | $135.69M | $143.73M | $56.13M | $59.52M | $88.35M | $115.63M | $9.97M | $14.28M | $19.00M | $1.15M |
| Goodwill | - | - | $0 | $0 | $48.65M | $48.65M | - | $1.87M | $1.87M | - |
| Total assets | $169.01M | $177.41M | $89.07M | $92.79M | $170.55M | $197.19M | $10.93M | $17.03M | $20.89M | $1.20M |
| Current liabilities | $18.34M | $11.58M | $3.90M | $6.47M | $4.40M | $2.48M | $1.32M | $2.53M | - | $3.90M |
| Total debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - | - | - |
| Total liabilities | $32.23M | $59.27M | $81.86M | $8.61M | $6.55M | $6.59M | $1.47M | $2.53M | $1.44M | $3.90M |
| Shareholders' equity | $81.08M | $62.45M | -$48.49M | $23.79M | $164.00M | $190.60M | $9.46M | $14.49M | $19.45M | -$2.70M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$62.34M | -$47.27M | -$39.53M | -$28.42M | -$28.91M | -$15.21M | -$13.86M | -$11.89M | -$14.94M | -$4.92M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | $9.0K |
| Free cash flow | - | - | - | - | - | - | - | - | - | -$4.93M |
| Investing cash flow | $10.79M | -$70.31M | -$45.29M | - | - | $11.04M | - | - | $23.26M | $1.0K |
| Financing cash flow | $53.81M | $133.52M | $33.02M | - | -$449.0K | $109.58M | $9.68M | $7.56M | $7.87M | $2.93M |
| Depreciation and amortization | - | - | - | - | - | $5.0K | $9.0K | $11.0K | $22.0K | $35.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -56.3% | -57.9% | - | -369.8% | -21.0% | -12.0% | -169.2% | -97.1% | -67.4% | - |
| Return on assets | -27.0% | -20.4% | -130.8% | -94.8% | -20.2% | -11.6% | -146.5% | -82.6% | -62.8% | -472.8% |
| Current ratio | 7.40 | 12.42 | 14.41 | 9.19 | 20.07 | 46.57 | 7.54 | 5.63 | - | 0.30 |
| Debt to equity | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $18.23M | $17.20M | $17.49M | $14.97M | $20.28M | $13.53M | $17.93M | $16.52M | $10.11M | $7.41M | $7.07M | $7.93M |
| Selling, general and admin | $4.64M | $3.98M | $3.99M | $4.10M | $4.46M | $4.43M | $6.77M | $3.99M | $4.40M | $3.46M | $3.27M | $3.27M |
| Operating income | -$22.87M | -$21.18M | - | -$19.07M | -$24.73M | -$17.96M | - | -$20.51M | -$14.50M | -$10.87M | -$10.34M | -$11.20M |
| Net income | -$31.63M | -$39.02M | -$10.45M | -$17.46M | -$11.22M | -$6.50M | -$44.62M | $76.97M | -$44.91M | -$23.63M | -$30.10M | -$9.91M |
| EPS, basic | -$0.27 | -$0.33 | -$0.10 | -$0.21 | -$0.13 | -$0.08 | - | $1.05 | -$0.92 | -$0.65 | - | -$0.33 |
| EPS, diluted | -$0.27 | -$0.33 | -$0.10 | -$0.21 | -$0.13 | -$0.08 | - | -$0.28 | -$0.92 | -$0.65 | - | -$0.33 |
| Diluted shares | 113.6M | 112.4M | - | 77.2M | 77.2M | 77.1M | - | 55.5M | 42.3M | 30.0M | - | 30.0M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.80M | $6.15M | $22.81M | $3.67M | $5.74M | $8.50M | $20.55M | $6.75M | $26.04M | $5.66M | $4.61M | $3.67M |
| Short-term investments | $81.95M | $104.94M | $110.53M | $89.73M | $101.83M | $116.39M | $119.63M | $71.44M | $57.57M | $37.21M | $46.49M | $55.94M |
| Current assets | $93.09M | $113.57M | $135.69M | $96.30M | $111.40M | $127.72M | $143.73M | $81.51M | $87.22M | $47.98M | $56.13M | $62.99M |
| Goodwill | - | - | - | - | - | - | - | - | - | - | $0 | - |
| Total assets | $126.09M | $146.67M | $169.01M | $129.86M | $144.91M | $161.31M | $177.41M | $114.58M | $120.48M | $80.82M | $89.07M | $96.07M |
| Current liabilities | $11.79M | $13.46M | $18.34M | $14.30M | $13.72M | $9.19M | $11.58M | $12.49M | $6.03M | $4.25M | $3.90M | $2.90M |
| Total debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $54.06M | $46.21M | $32.23M | $38.80M | $38.88M | $46.73M | $59.27M | $38.52M | $128.98M | $95.55M | $81.86M | $60.47M |
| Shareholders' equity | $33.01M | $44.76M | $81.08M | $35.36M | $50.33M | $58.89M | $62.45M | $20.36M | -$64.19M | -$70.42M | -$48.49M | $35.60M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.68M | -$22.61M | -$14.09M | -$14.48M | -$17.71M | -$16.06M | -$18.99M | -$11.77M | -$7.77M | -$8.74M | -$9.13M | -$12.25M |
| Investing cash flow | $23.24M | $5.96M | -$20.46M | $12.40M | $14.96M | $3.89M | -$47.38M | -$12.80M | -$19.91M | $9.78M | $10.08M | -$25.03M |
| Financing cash flow | - | - | $53.69M | $0 | $0 | $115.0K | $80.17M | $5.28M | $48.07M | $1.0K | $0 | $0 |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 7.90 | 8.44 | 7.40 | 6.74 | 8.12 | 13.91 | 12.42 | 6.53 | 14.48 | 11.30 | 14.41 | 21.73 |
| Debt to equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 |
Source: XBRL data Eledon Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-18, first reported Nov 16, 2020.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ELDN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ELDN | - | - | -$98.56M | - | $232.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
ELDN FAQ
5 questionsIs ELDN profitable?
No. Eledon Pharmaceuticals Inc. reported a net loss of $98.56M for the twelve months ended Jun 30, 2026.How much cash and debt does ELDN have?
Eledon Pharmaceuticals Inc. reported $6.80M in cash and cash equivalents and $0 of debt on its most recent balance sheet in SEC filings.What is ELDN earnings per share?
Diluted earnings per share were -$0.91 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did ELDN last report financial results?
The latest statements here come from Eledon Pharmaceuticals Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this ELDN financial data come from?
Quantisnow builds these statements from the structured XBRL data Eledon Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.